Baili Tianheng: The first subject in the Phase III clinical trial of BL-M07D1 for injection has been enrolled.

Baili Tianheng Announcement: The phase III clinical trial of the innovative biotherapeutic injection BL-M07D1, independently developed by the company, for HER2 low-expressing recurrent or metastatic breast cancer has recently completed the first subject enrollment. BL-M07D1 is a novel ADC targeting HER2, with the best potential in its class, and has demonstrated significant anti-tumor efficacy in clinical trials. Currently, BL-M07D1 is undergoing 12 clinical trials both domestically and internationally, covering indications such as second-line and above HER2-positive breast cancer, HER2-positive breast cancer adjuvant therapy, HER2-positive breast cancer neoadjuvant therapy, HER2 low-expressing breast cancer, as well as lung cancer, gastrointestinal tumors, urogenital tumors, and gynecological tumors.